Core Viewpoint - The company emphasizes the importance of safety in production as a fundamental principle for its development, especially in light of recent safety incidents in the industry [2]. Group 1 - The company is committed to high-quality development and will implement various measures to strengthen safety foundations and improve operational quality [2]. - The company aims to ensure sustainable and healthy growth in its operations [2].

Group 1 - The core viewpoint of the article is that Yong'an Pharmaceutical's subsidiary, Yong'an Kangjian Yijian, is progressing as planned in expanding its offline channel for self-branded products and is currently in discussions with mainstream chain channels [2] Group 2 - Yong'an Pharmaceutical is actively engaging in communication and negotiation with major retail chain partners to enhance its market presence [2] - The company is focused on a structured approach to advance its product distribution strategy [2]

Core Viewpoint - Yong'an Pharmaceutical reported that as of October 10, 2025, the number of shareholders reached 58,256 [2] Company Summary - Yong'an Pharmaceutical's shareholder count is projected to be 58,256 by October 10, 2025 [2]

Core Viewpoint - The management of Yong'an Pharmaceutical emphasizes the importance of fundamental performance as the core support for stock price, aiming to enhance profitability and intrinsic value as primary tasks [2] Group 1: Business Strategy - The company is focused on strengthening its competitive advantage in the taurine business through market expansion, research and development innovation, cost reduction, efficiency improvement, and management optimization [2] - Yong'an Pharmaceutical plans to diversify by expanding into surrounding products and downstream processing markets related to taurine, aiming to cultivate new growth points for performance [2] Group 2: Management Commitment - The management is committed to improving operational quality and will continue to implement various operational measures to enhance the company's performance [2]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) is progressing as planned with its offline channel for self-owned brand products through its subsidiary Yong'an Kangjian Yijian, currently in discussions with mainstream chain channels [1] Group 1 - Yong'an Kangjian Yijian is advancing its offline channel strategy in an orderly manner [1] - The company is in the communication and negotiation phase with major chain channels [1]

Core Points - Yong'an Pharmaceutical announced the convening of the 9th temporary meeting of the 7th Board of Directors on September 24, 2025, and the second temporary shareholders' meeting on October 14, 2025, to review proposals regarding changes in business scope, increasing the number of board members, and amendments to the articles of association [1] - The company has completed the industrial and commercial change registration and the filing of the articles of association, and has obtained a new business license issued by the Hubei Provincial Market Supervision Administration [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-61 潜江永安药业股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 9 月 24 日及 2025 年 10 月 14 日分别召开第七届董事会第九次临时会议及 2025 年第二次临时 股东会，审议通过了《关于变更经营范围、增加董事会成员人数并修订<公司章 程>的议案》。具体内容见公司在中国证监会指定信息披露媒体巨潮资讯网 （http://www.cninfo.com.cn）披露的《第七届董事会第九次临时会议决议公告》 （公告编号：2025-53）、《关于变更经营范围、增加董事会成员人数并修订< 公司章程>以及制定、修订部分治理制度的公告》（公告编号：2025-55）、《2025 年第二次临时股东会决议公告》（公告编号：2025-58）。 近日，公司已办理完成工商变更登记及《公司章程》备案手续，并取得了由 湖北省市场监督管理局换发的《营业执照》，具体情况如下： 一、本次经营范围变更情况 ...

Core Points - The company held a staff representative meeting on October 17, 2025, where Mr. Xia Sha was elected as a staff representative director for the seventh board of directors [1] - Mr. Xia Sha meets the qualifications and conditions for a director as per the Company Law and relevant regulations [1] - The composition of the seventh board of directors complies with legal requirements, ensuring that the number of directors who are also senior management or staff representatives does not exceed half of the total number of directors [1] Summary of Mr. Xia Sha's Profile - Mr. Xia Sha, born in May 1988, holds a bachelor's degree and has held various positions within the company, including deputy director and director of the electrical instrumentation workshop, and deputy and head of the engineering department [1] - Currently, Mr. Xia Sha serves as the head of the supply department [1] Compliance and Relationship - Mr. Xia Sha does not hold any shares in the company and has no relationships with shareholders holding more than 5% of the company's shares or with other directors and senior management [2] - He is not subject to any disqualifications as per the Company Law and relevant regulations, and has not faced penalties from regulatory bodies [2]

Core Viewpoint - Yong'an Pharmaceutical announced the election of Mr. Xia Sha as the employee representative director of the company's seventh board of directors during the employee representative assembly held on October 17, 2025 [1] Group 1 - The employee representative assembly was held on October 17, 2025 [1] - Mr. Xia Sha was elected as the employee representative director [1] - The seventh board of directors will consist of Mr. Xia Sha and six non-employee representative directors elected at the 2023 annual shareholders' meeting [1] - The term of the newly elected board members will last until the expiration of the seventh board's term [1]

特此公告。 潜江永安药业股份有限公司 董 事 会 二○二五年十月二十日 附件： 职工代表董事简历： 夏沙先生：1988年5月出生，本科学历。曾任公司电仪车间副主任、主任，公 司工程部副部长、部长。现任公司供应部部长。 证券代码：002365 证券简称：永安药业 公告编号：2025-60 潜江永安药业股份有限公司 关于选举第七届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 为保证公司董事会的规范运作，根据《公司法》及《公司章程》的相关规定， 潜江永安药业股份有限公司（以下简称"公司"）于2025年10月17日召开了职工代 表大会，经民主讨论、表决，选举夏沙先生（简历见附件）为公司第七届董事会职 工代表董事，夏沙先生将与公司2023年年度股东大会选举产生的六名非职工代表董 事共同组成公司第七届董事会，任期自本次职工代表大会选举通过之日起至公司第 七届董事会任期届满之日止。 夏沙先生符合《公司法》《深圳证券交易所上市公司自律监管指引第1号—— 主板上市公司规范运作》及《公司章程》规定的有关董事任职资格和条件。本次选 举职工代表董事后，公司 ...